Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Intravitreal Injection of a Rho-Kinase Inhibitor (Fasudil) for Recent-Onset Nonarteritic Anterior Ischemic Optic Neuropathy Publisher Pubmed



Sanjari N1 ; Pakravan M1 ; Nourinia R1 ; Esfandiari H1 ; Hafezimoghadam A2 ; Zandi S2 ; Nakao S2 ; Shahheidari MH1 ; Jamali A3 ; Yaseri M4 ; Ahmadieh H1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Ophthalmic Research Center, Ophthalmology Department, Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences, Pasdaran Ave. Boostan 9 St., Tehran, 1666694516, Iran
  2. 2. Center for Excellence in Functional and Molecular Imaging, Brigham and Women's Hospital, Department of Radiology, Harvard Medical School, Boston, MA, United States
  3. 3. Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

Source: Journal of Clinical Pharmacology Published:2016


Abstract

This study evaluated the effects of intravitreal injection of fasudil (IVF), a Rho-kinase inhibitor, in cases of recent-onset nonarteritic anterior ischemic optic neuropathy (NAION). In this interventional case series, 13 eyes of 13 patients diagnosed with NAION within 14 days of onset were included. The affected eyes received a 0.025 mg/0.05 mL IVF. Functional and structural outcomes were assessed 1 and 3 months following treatment. Best corrected visual acuity (BCVA) was the main outcome measured, with mean deviation (MD) index of the VF test and peripapillary retinal nerve fiber layer thickness as secondary measures. There was a statistically significant improvement in the patients' BCVA 1 and 3 months following IVF; BCVA improved from 1.69 ± 0.55 logMAR at baseline to 0.98 ± 0.47 and 0.93 ± 0.51 logMAR at 1 and 3 months, respectively (P =.004). The change in BCVA was not significant between month 1 and month 3 (P =.22). Peripapillary retinal nerve fiber layer thickness decreased from 173.5 ± 29.28 μm in the baseline evaluation to 85.8 ± 8.8 μm at 1 month, and 62.9 ± 5.97 μm at 3 months (P =.003). MD values changed from 24.60 ± 3.80 to 21.0 ± 6.10 and 20.5 ± 6.50 at 1 and 3 months, respectively (P =.007 and.005, respectively). This pilot study suggests that IVF may be an effective treatment for patients with recent-onset NAION. Larger studies are required to establish the therapeutic role of fasudil for NAION. © 2015, The American College of Clinical Pharmacology.
Related Docs
1. The Effect of High-Dose Steroids, and Normobaric Oxygen Therapy, on Recent Onset Non-Arteritic Anterior Ischemic Optic Neuropathy: A Randomized Clinical Trial, Graefe's Archive for Clinical and Experimental Ophthalmology (2016)
2. The Ocular Hypotensive Efficacy of Topical Fasudil, a Rho-Associated Protein Kinase Inhibitor, in Patients With End-Stage Glaucoma, American Journal of Therapeutics (2016)
3. The Effect of Systemic Erythropoietin and Oral Prednisolone on Recent-Onset Non-Arteritic Anterior Ischemic Optic Neuropathy: A Randomized Clinical Trial, Graefe's Archive for Clinical and Experimental Ophthalmology (2020)
4. Intravitreal Injection of a Rho-Kinase Inhibitor (Fasudil) Combined With Bevacizumab Versus Bevacizumab Monotherapy for Diabetic Macular Oedema: A Pilot Randomised Clinical Trial, British Journal of Ophthalmology (2019)
Experts (# of related papers)
Mehdi Yaseri (3)